KOCAA
RETA

Knights of Columbus Asset Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,433
Closed -$1.34M – 344
2021
Q1 		$1.34M Buy
13,433
+429
+3% +$50K 0.13% 231
2020
Q4 		$1.61M Buy
+13,004
New +$1.71M 0.17% 213

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Knights of Columbus Asset Advisors's RETA Position: Q2 2021 in Review

Knights of Columbus Asset Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 13,433 shares — an estimated $1.34M sold.

Knights of Columbus Asset Advisors first reported a position in RETA in Q4 2020 and held it in 2 quarters. The position peaked at $1.61M in Q4 2020. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

  • Knights of Columbus Asset Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 13,433 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $1.34M.
  • Knights of Columbus Asset Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2020 and held it in 2 quarters.
  • Knights of Columbus Asset Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.61M in Q4 2020.
  • 194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.